BOYNTON BEACH, Fla., Oct. 8, 2003 (PRIMEZONE) -- Harvey Grossman, President and Chief Strategic Officer of Jacobson Resonance Enterprises, Inc. (OTCBB:JRSE) announced today that the Company's Canadian licensee, Bio Resonance Technology, Inc., projects that JRSE will begin receiving annualized six-figure royalties in the last quarter of 2004. We believe the Company's estimated worldwide revenue projections for the years 2004 through 2008 will tap into a $300 Billion+ market space. The Company's overall estimated revenue projections for the years 2004 through 2008 will be forthcoming in a series of news releases beginning today. These projections are based on our rebuilt management team's current analysis of market trends. The projections flow from our newly identified target markets, reasonable time lines for execution, and a growing scientific and technology base. We believe that our business model for 2004 and 2005 is important as this acts as a launch pad for subsequent success.
Chronic pain has been said to be the most costly health problem in Canada and America. According to the Chronic Pain Association of Canada nearly six million people suffer from chronic pain at a cost to Canadians of about $10 billion. In America, for example, according to NewsRx.com, the American Pain Foundation, National Institute of Neurological Disorders and Stroke and the Bureau of National Affairs, approximately seventy (70) million Americans suffer from chronic pain from all causes. It costs America about $100 billion annually. These annual costs include forty (40) million doctor visits and five hundred and fifteen (515) million lost workdays. The statistical percentages for chronic pain sufferers in the European Union and associated nations (23 nations with 600,000,000 people) match the USA. Therefore, in Europe approximately 152,000,000 people suffer from chronic pain at an annual cost of about $218 billion.
Our goal at JRSE is to penetrate 3% to 5% of this $300+ billion worldwide chronic pain market segment within ten years. (1)
Throughout the world, using our patented Magnetic Resonance Therapy (MRT) in Institutional Review Board approved clinical research projects, and in clinical settings in Europe and Canada, thousands of people have reported profound and long-lasting relief from pain whatever the cause. Many clients reported quality of life restored. Along with profound pain relief, the overwhelming majority of research subjects and clinical clients report a deep sense of relaxation, and as days passed, many felt rejuvenated.
Breakout of Worldwide Commercial Initiatives
The foundation for our projected commercial success in the first couple of years would be based on worldwide initiatives (except in the USA) in pain management and the leisure/spa relaxation and rejuvenation arenas. At this time the Canadian projections reflect only the pain management arena.
JRSE Royalty Revenue Projections in US Dollars From Canada, 2004 -
2008
2005 2006 2007 2008
(2)Canada/ Bio 387,500 775,000 1,325,000 2,698,822
Resonance
Technology, Inc.
Bio Resonance Technology, Inc. of Winnipeg is achieving growing acceptance from the Canadian Medical Community and has gained support of key third party insurers, government agencies and physicians. Health Canada has granted licensing rights for the treatment of reduction of pain associated with arthritic conditions. We expect to begin accelerated commercialization of Magnetic Resonance Therapy (MRT) treatments using Jacobson Resonators for the alleviation of pain associated with arthritic conditions (including lower back pain) in the fourth quarter of 2004.
Bio Resonance Technology, Inc. is implementing a two- pronged approach in gaining access to this $10 billion a year chronic pain market segment afflicting about six million Canadians: 1) Company owned and operated pain management centers located in major cities, and 2) distribution of Jacobson Resonators to medical facilities (including pain management centers, hospitals, physician clinics, chiropractors and physiotherapists) on a pay per use, lease or outright purchase basis. You can visit the Company's web site at www.bioresonance.ca.
As in Europe, there may also be an opportunity in Canada (that we are currently exploring) to enter the leisure/spa arena using Jacobson Resonance for relaxation purposes. If this materializes we will reflect the increased revenues in future announcements.
JRSE is an emerging worldwide leader in magnetic resonance technology, whose main focus is the eradication of human suffering. The Company's technology base has the potential for multiple industry applications including the fields of medicine, spa and leisure arena, food and beverage, pharmaceuticals, energy and the environment.
Update:
1. It should be noted that the offshore treatment center in the Bahamas will open in the forth quarter of this year, 2003, and not as erroneously stated in our last press release ("Jacobson Resonance Enterprises, Inc Announces Corporate Plans for 2004/2005, September 29, 2003.") "the last quarter of 2004."
2. There are a couple of corrections that should be noted from the September 17, 2003 press release entitled "Jacobson Resonance Enterprises, Inc.'s Scientific Base Gains Worldwide Recognition in Multi-Billion Dollar Market Space."
A. Paragraph No. 6 should read ... On November 27, 2000.
B. Paragraph No. 7 should read: Proteins, m-RNA (instead of in-RNA).
C. Paragraph No. 11 should read: ... while using Jacobson Resonance
were studied at the University of Oklahoma ... (instead of
studies)
D. Paragraph No. 12, should read: ... dramatic growth effects of soya
and mung bean sprouts ... (instead of ... dramatic growth effects
soya and mung bean ...).
E. Paragraph No. 12, further in should read: . . .the enhanced
diffusion rate of resonated water compared to non-resonated,
across a semi-permeable membrane. . .(across a semi-permeable
membrane was inadvertently left out).
(1)(2) Although we have set what we believe is a responsible goal there is no assurance that we will achieve this anticipated market penetration. We recognize that there is competition in this marketplace, and that to achieve our goal, we will need to establish significant revenue streams to avoid the need for additional funding, as well as FDA, EU and Health Canada clearances for certain applications of our resonator technology.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The matters covered by such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements of the Company to differ materially from those contemplated or implied by such forward-looking statements. Included in these risks and other factors are funding availability, competition from better-financed companies and required regulatory clearances. For further information, contact Harvey Grossman at (561) 752.4141.
-0-
CONTACT Jacobson Resonance Enterprises, Inc.
Harvey Grossman
(561) 752-4141